Related Experiment Video
Updated: Aug 4, 2025
Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
C5a complement levels in clinical remission AQP4-IgG-positive NMO patients
Analisa Manin1, Mariano E Justo2,3, Juliana Leoni3
1División Neurología, Hospital Gral. de Agudos Dr. José María Ramos Mejía, Bs. As, Argentina, Centro Argentino de Neuroinmunología (CADENI), Facultad de Medicina, Universidad de Buenos Aires, CABA, Cuidad Autónoma de Buenos Aires, Argentina. analisamanin@gmail.com.
Elevated plasma C5a levels were observed in patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) during remission. This finding suggests C5a may serve as a potential biomarker for NMOSD disease activity.
Area of Science:
- Neuroimmunology
- Complement System Biology
Background:
- Neuromyelitis Optica Spectrum Disorders (NMOSD) are CNS inflammatory conditions.
- The complement system plays a significant role in NMOSD pathogenesis.
- Antibody-mediated damage is a hallmark of NMOSD.
Purpose of the Study:
- To quantify serum and plasma levels of complement factors C3, C4, and C5a.
- To compare these levels in patients with Aquaporin-4 IgG-positive (AQP4-IgG+) NMOSD in remission versus healthy controls.
- To explore the potential of these factors as biomarkers for NMOSD.
Main Methods:
- Serum and plasma samples were collected from 12 AQP4-IgG+ NMOSD patients in remission and 19 healthy controls.
- Complement factors C3 and C4 were measured in serum.
- Complement factor C5a was measured in plasma using specific assays.
- AQP4 antibodies were quantified using a cell-binding assay (CBA).
Main Results:
- Mean serum concentrations of C3 and C4 in NMOSD patients were within normal ranges and not significantly different from healthy controls.
- Plasma levels of C5a showed a statistically significant elevation in NMOSD patients compared to healthy controls (p=0.0444).
- No significant difference was found in C3 and C4 levels between the groups.
Conclusions:
- Plasma C5a levels are significantly higher in AQP4-IgG+ NMOSD patients during remission.
- C5a warrants further investigation as a potential biomarker for NMOSD disease activity.
- Prospective studies with larger cohorts are recommended to validate these findings.
